Non-HDL / Total Cholesterol Ratio

The Non-HDL to Total Cholesterol Ratio is a comprehensive measure of all the cholesterol in your bloodstream that has the potential to contribute to plaque buildup in your arteries. It’s calculated by dividing non-HDL cholesterol — which represents total cholesterol minus HDL cholesterol — by total cholesterol.

Non-HDL cholesterol includes all atherogenic lipoproteins such as LDL, VLDL, IDL, and lipoprotein(a). These particles carry cholesterol to tissues throughout the body but, when present in excess, can deposit it into the arterial walls, accelerating atherosclerosis. By contrast, HDL cholesterol plays a protective role, helping clear cholesterol from the bloodstream. This ratio therefore captures the proportion of harmful cholesterol relative to total cholesterol, offering a clearer view of overall cardiovascular risk than total cholesterol alone.

The Non-HDL to Total Cholesterol Ratio is a strong predictor of atherosclerotic cardiovascular disease (ASCVD) events. It correlates with the total number of atherogenic particles circulating in the blood — an important distinction, since even individuals with “normal” LDL levels can have elevated non-HDL cholesterol if other lipoproteins like VLDL or Lp(a) are high.

Research shows that this ratio performs particularly well in identifying risk among people with elevated triglycerides, metabolic syndrome, or insulin resistance, where LDL-C alone often underestimates cardiovascular risk. Unlike LDL cholesterol, non-HDL cholesterol accounts for all cholesterol-containing particles that promote arterial plaque formation. Because of this, it has been described as a “total atherogenic load” marker, giving clinicians a more complete picture of cardiovascular risk.

Another advantage is its clinical convenience. The ratio can be measured accurately in both fasting and non-fasting states, which means it can be used in routine check-ups without the need for strict pre-test conditions. This makes it a practical and reliable tool for population-level screening and long-term monitoring.

While traditional lipid ratios — like LDL to HDL and LDL-C to ApoB — remain central to cardiovascular risk assessment, the Non-HDL to Total Cholesterol Ratio offers an additional perspective by summarising the total burden of atherogenic lipoproteins.

The LDL/HDL ratio captures the balance between atherogenic LDL particles and protective HDL particles; a higher ratio is linked to greater arterial plaque formation and a higher risk of major adverse cardiovascular events (MACE). The LDL-C/ApoB ratio, meanwhile, gives insight into LDL particle size — lower ratios indicate smaller, denser LDL particles, which are more likely to penetrate vessel walls and contribute to inflammation.

Beyond lipid-only ratios, markers like the Monocyte-to-HDL Ratio (MHR) and Neutrophil-to-HDL Ratio (NHR) incorporate inflammation into cardiovascular assessment. Elevated MHR reflects increased monocyte-driven inflammation and diminished HDL-mediated protection, while high NHR indicates heightened neutrophil activity and oxidative stress. Both are strongly linked to coronary artery disease severity and long-term mortality.

By contrast, the Non-HDL to Total Cholesterol Ratio takes a broader lipid-centric approach, summarising all cholesterol carried by atherogenic particles rather than focusing on specific subtypes or inflammatory mediators. Used alongside markers like MHR, NHR, ApoB, and LDL/HDL, it rounds out a multidimensional picture of cardiovascular risk that integrates both lipid metabolism and inflammation.

If your Non-HDL to Total Cholesterol Ratio is elevated, it suggests that a high proportion of your total cholesterol is carried by particles that promote atherosclerosis. Improving this ratio involves both lowering atherogenic lipoproteins and raising protective HDL levels.

Adopt a heart-healthy, anti-inflammatory diet that emphasizes whole foods, fibre-rich vegetables, omega-3 fatty acids, and healthy fats such as olive oil and nuts. Reducing refined carbohydrates, trans fats, and alcohol can lower VLDL and triglyceride levels, directly improving non-HDL cholesterol. Regular aerobic and resistance exercise helps raise HDL, improve lipid transport, and reduce the overall number of atherogenic particles.

If lifestyle changes aren’t sufficient, your clinician may consider further testing — such as ApoB, Lp(a), or LDL particle number — to better characterise your lipid profile. In some cases, statins, PCSK9 inhibitors, or fibrates may be used to target specific lipid fractions.

The Non-HDL to Total Cholesterol Ratio is a simple, practical, and powerful tool that can uncover hidden cardiovascular risk, especially in those with metabolic dysfunction or high triglycerides. By optimising both lipid balance and metabolic health, you can meaningfully reduce your risk of heart disease over time.

1. Brunner, F. J., Waldeyer, C., Ojeda, F., et al. (2019). Application of non-HDL cholesterol for population-based cardiovascular risk stratification: Results from the Multinational Cardiovascular Risk Consortium. Lancet, 394(10215), 2173–2183. https://doi.org/10.1016/S0140-6736(19)32519-X
   
   

2. Miller, M., Stone, N. J., Ballantyne, C., et al. (2011). Triglycerides and cardiovascular disease: A scientific statement from the American Heart Association. Circulation, 123(20), 2292–2333. https://doi.org/10.1161/CIR.0b013e3182160726
   
   

3. Bays, H. E., Kirkpatrick, C. F., Maki, K. C., et al. (2024). Obesity, dyslipidemia, and cardiovascular disease: A joint expert review from the Obesity Medicine Association and the National Lipid Association. Journal of Clinical Lipidology, 18(3), e320–e350. https://doi.org/10.1016/j.jacl.2024.04.001
   
   

4. Arsenault, B. J., Rana, J. S., Stroes, E. S., et al. (2009). Beyond LDL cholesterol: The contributions of non-HDL cholesterol, triglycerides, and total cholesterol/HDL ratio to coronary heart disease risk in healthy adults. Journal of the American College of Cardiology, 55(1), 35–41. https://doi.org/10.1016/j.jacc.2009.07.057
   
   

5. Jiang, M., Yang, J., Zou, H., et al. (2022). Monocyte-to-HDL cholesterol ratio (MHR) and the risk of all-cause and cardiovascular mortality: A nationwide cohort study in the United States. Lipids in Health and Disease, 21(1), 30. https://doi.org/10.1186/s12944-022-01638-6
   
   

6. Chen, J., Wu, K., Cao, W., Shao, J., & Huang, M. (2023). Association between monocyte-to-HDL cholesterol ratio and multi-vessel coronary artery disease: A cross-sectional study. Lipids in Health and Disease, 22(1), 121. https://doi.org/10.1186/s12944-023-01897-x
   
   

7. Liu, S. L., Feng, B. Y., Song, Q. R., et al. (2022). Neutrophil-to-HDL cholesterol ratio predicts adverse cardiovascular outcomes in subjects with pre-diabetes: A large cohort study from China. Lipids in Health and Disease, 21(1), 86. https://doi.org/10.1186/s12944-022-01695-x
   
   

8. Ren, H., Zhu, B., Zhao, Z., et al. (2023). Neutrophil-to-HDL cholesterol ratio as the risk mark in patients with type 2 diabetes combined with acute coronary syndrome: A cross-sectional study. Scientific Reports, 13(1), 7836. https://doi.org/10.1038/s41598-023-35050-6